Evidence map›Paper›PMID 32019343›Full record

Trial reportCirculation. Cardiovascular interventions2020

Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention: Insights From DIVA Trial.

Faisal Latif, Lauren Uyeda, Robert Edson, Deepak L Bhatt, Steven Goldman, David R Holmes, Sunil V Rao, Kendrick Shunk, Kul Aggarwal, Barry Uretsky and 13 more

Registry-linked trialOpen access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Circulation. Cardiovascular interventions, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01121224 (CSP #571 - Drug-eluting Stents vs. Bare Metal Stents in Saphenous Vein Graft Angioplasty), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01121224 phase4completednot on this map

CSP #571 - Drug-eluting Stents vs. Bare Metal Stents in Saphenous Vein Graft Angioplasty (DIVA)

TypeinterventionalSponsorVA Office of Research and DevelopmentRan2012 to 2016Enrolled597ConditionsSaphenous Vein Graft AtherosclerosisArmsBare Metal Stent, Drug-Eluting Stent, Blinded clopidogrel, Placebo, Thienopyridine (open-label)
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Optimization and Standardization of Plant-Derived Vascular Scaffolds.International journal of molecular sciences · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Faisal LatifVA Medical Center, Oklahoma City (F.L.).
Lauren UyedaVA Cooperative Studies Program Coordinating Center, Mountain View, CA (L.U., R.E., M.-C.S.).
Robert EdsonVA Cooperative Studies Program Coordinating Center, Mountain View, CA (L.U., R.E., M.-C.S.).
Deepak L BhattVA Boston Healthcare System, MA (D.L., S.K., R.S.V).
Steven GoldmanUniversity of Arizona Sarver Heart Center, Tucson (S.G.).
David R HolmesMayo Clinic, Rochester, MN (D.R.H.).
Sunil V RaoDurham VA Medical Center, NC (S.V.R.).
Kendrick ShunkSan Francisco VA Medical Center, CA (K.S.).
Kul AggarwalHarry S Truman VA Hospital, Columbia, MO (K.A.).
Barry UretskyCentral Arkansas Veterans Health System, Little Rock (B.U.).
Islam BoladIndiana University School of Medicine, Indianapolis (I.B.).
Khaled ZiadaUniversity of Kentucky, Lexington (K.Z.).
Edward McFallsVA Medical Center, Minneapolis, MN (E.M.).
Anand IrimpenSoutheast Louisiana Veterans Health Care System, New Orleans (A.I.).
Huu Tam TruongVA Loma Linda Medical Center, CA (H.T.T.).
Scott KinlayVA Cooperative Studies Program Coordinating Center, Mountain View, CA (L.U., R.E., M.-C.S.).
Vasilios PapademetriouVA Medical center Washington DC (V.P.).
Raghava S VelagaletiVA Boston Healthcare System, MA (D.L., S.K., R.S.V).
Bavana V RanganMinneapolis Heart Institute Foundation, MN (B.V.R., E.S.B.).
Kreton MavromatisAtlanta VA Healthcare System, GA (K.M.).
Mei-Chiung ShihVA Cooperative Studies Program Coordinating Center, Mountain View, CA (L.U., R.E., M.-C.S.).
Subhash BanerjeeDallas VA Medical Center, TX (S.B.).
Emmanouil S BrilakisMinneapolis Heart Institute Foundation, MN (B.V.R., E.S.B.).
Harvard University · USMayo Clinic in Arizona · US

Funding

Prolonged Clopidogrel Use After Drug-Eluting and Bare-Metal Coronary StentingI01CX000440 · VA · VA BOSTON HEALTH CARE SYSTEM · PI KINLAY, SCOTT · 2012 to 2014
–
Rationalizing Duration of Dual Antiplatelet Therapy After Coronary StentingI01CX001549 · VA · VA BOSTON HEALTH CARE SYSTEM · PI KINLAY, SCOTT · 2017 to 2021
–
CSRD VA I01 CX000440CSRD VA I01 CX001549
6 · The paper itself

Abstract

backgroundDirect stenting without pre-dilation or post-dilation has been advocated for saphenous vein graft percutaneous coronary intervention to decrease the incidence of distal embolization, periprocedural myocardial infarction, and target lesion revascularization.

methodsWe performed a post hoc analysis of patients enrolled in the DIVA (Drug-Eluting Stents Versus Bare Metal Stents in Saphenous Vein Graft Angioplasty; NCT01121224) prospective, double-blind, randomized controlled trial. Patients were stratified into stent-only and balloon-stent groups. Primary end point was 12-month incidence of target vessel failure (defined as the composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization). Secondary end points included all-cause death, stent thrombosis, myocardial infarction, and target lesion revascularization during follow-up.

resultsOf the 575 patients included in this substudy, 185 (32%) patients underwent stent-only percutaneous coronary intervention. Patients in the stent-only versus balloon-stent group had similar baseline characteristics and similar incidence of target vessel failure at 12-months (15% versus 19%; hazard ratio, 1.34 [95% CI, 0.86-2.08];

conclusionsIn patients undergoing percutaneous coronary intervention of de novo saphenous vein graft lesions, there was no difference in target vessel failure at 12 months and long-term follow-up in the stent-only versus the balloon-stent group; however, the incidence of stent thrombosis was lower in the stent-only group, as was target vessel myocardial infarction. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01121224.

Indexed as

StentsAgedAngioplastyAngioplasty, Balloon, CoronaryCoronary Artery BypassCoronary ThrombosisDouble-Blind MethodFemaleGraft Occlusion, VascularHumansMaleMiddle AgedMyocardial InfarctionProspective StudiesRisk FactorsSaphenous Veinangioplastydilatationincidencemyocardial infarctionstents

Identifiers

PMID32019343
PMCPMC7053803
OpenAlexW3006081861

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.